GSK plc reported on April 17, 2024, that new data shows Shingrix maintains a 79.7% efficacy against shingles in adults aged 50+ for six to eleven years post-vaccination, with high protection levels still at 82.0% at year 11. This event supports public immunization strategies and confirms long-term protection without new safety concerns identified.